Table of Contents
In the field of pharmaceutical APIs and intermediates, every technological breakthrough means a leap in the industry. Today, we are proud to announce that (2S,5R)-benzyloxyaminopiperidine-2-carboxylic acid ethyl ester oxalate, the key intermediate of avibactam sodium, has been successfully commercialized and mass-produced at Tianming Pharmaceutical!
This is not only a reflection of our technical strength, but also a shot in the arm for global antibiotic drug development and production.
As a high-tech enterprise specializing in the research, development, production and sales of APIs and intermediates, Tianming always adheres to the concept of “quality-oriented, innovation-driven”, and is committed to providing high-quality APIs and intermediates for global pharmaceutical companies.
The company has advanced production equipment and strict quality management system, and has passed ISO9001 and other international certifications to ensure the stability and reliability of each batch of products.
Over the years, Tianming has been deeply engaged in the fields of antibiotics, anti-virus and anti-tumor, and has accumulated rich technical experience and industry resources. The successful mass production of avibactam sodium intermediates is the result of years of efforts by the technical team.
Avibactam Sodium is a new type of β-lactamase inhibitor, which, in combination with cephalosporin antibiotics, can significantly enhance the antibacterial activity against multi-drug-resistant bacterial infections.
As the key intermediate of Avibactam Sodium, (2S,5R)-benzyloxyaminopiperidine-2-carboxylic acid ethyl ester oxalate has been a “choke point” in the industry because of its complicated synthesis process and high technological threshold.
CAS. No | 1416134-48-9 |
Chemical name | (2S,5R)-Benzyloxyaminopiperidin-2-carboxylic acid ethyl ester oxalate |
Molecular formula | C17H24N2O7 |
Molecular weight | 368.38 |
Our products have the following core advantages:
High purity: the purity is stabilized at over 99.5%, which meets the demand of high-end preparations.
Scale production: annual production capacity reaches 1-5 tons, which can be stably supplied to the global market.
Cost Advantage: Through process optimization, the production cost is significantly reduced, providing customers with cost-effective options.
The synthesis process of avibactam sodium intermediates is complex, involving multi-step reactions and extremely demanding in terms of stereo configuration. In the laboratory stage, we had faced the following challenges:
Stereoselectivity control: how to synthesize the (2S,5R) configuration efficiently and avoid the generation of by-products?
Process scale-up challenges: How to solve the problem of successful laboratory trials but sudden yield drop when scaling up?
Impurity control: How to ensure the high purity of intermediates and final products in each step of the reaction?
In the face of these difficulties, our R&D team rose to the challenge, and after hundreds of experiments and process optimization, we finally overcame the following key technologies:
Chiral catalytic technology: We have developed a highly efficient chiral catalyst and successfully realized the highly selective synthesis of (2S,5R) configuration.
Continuous flow reaction technology: A continuous flow reactor was introduced to solve the mass and heat transfer problems in the process scale-up, and the yield was greatly improved.
Impurity control system: Strict impurity control standards and analytical methods were established to ensure stable product purity.
From laboratory to commercial production, every step is full of challenges. Tianming’s production team worked closely with the R&D team to overcome a series of difficulties in equipment selection, process parameter optimization, and quality control.
In the end, a systematic production line for avibactam sodium intermediates was successfully built and stable mass production was realized.
The successful mass production of avibactam sodium intermediates marks a solid step for Tianming in the field of high-end APIs. In the future, we will continue to uphold the concept of “innovation-driven, customer-first” to provide more high-quality products and services for global pharmaceutical companies.
We look forward to cooperating with you and jointly promoting the progress and development of the pharmaceutical industry!
24-hour professional docking channel has been opened
📧 Email: damon.wang@sdsihuanpharm.com
📱 WhatsApp: +86 133 6541 4469
Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.
This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.
Comprehensive guide to 2-methylpentanoic acid’s pharmaceutical synthesis roles, industrial applications (lubricants/flavors), production optimization, GMP quality parameters, and global regulatory compliance requirements.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.